[Skip to Navigation]
June 2012

Systemic and Ocular Risks Associated With Therapies for Macular Degeneration: Clarification vs Confusion—Reply

Author Affiliations

Author Affiliations: Duke University, Durham, North Carolina.

Arch Ophthalmol. 2012;130(6):806-807. doi:10.1001/archophthalmol.2012.100

In reply

We agree with Friberg and colleagues that caution is always warranted in the conduct and interpretation of nonrandomized treatment comparisons. The important caveats they mention were discussed in our article.1 Additional studies are needed to define the relative treatment benefits and risks of these alternative approaches to a major ocular problem in older adults.

Add or change institution